Occidental Asset Management’s Matinas BioPharma MTNB Stock Holding History

Occidental Asset Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-400	Closed	-$20K	–	207
2021 Q4	$20K	Buy	+400	New	+$21.4K	﹤0.01%	207
2021 Q3	–	Sell	-240	Closed	-$9K	–	209
2021 Q2	$9K	Buy	+240	New	+$10.3K	﹤0.01%	201

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Occidental Asset Management's MTNB Position: Q1 2022 in Review

Occidental Asset Management sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 400 shares — an estimated $20K sold.

Occidental Asset Management first reported a position in MTNB in Q2 2021 and held it in 2 quarters. The position peaked at $20K in Q4 2021. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

Occidental Asset Management reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
Occidental Asset Management sold 400 Matinas BioPharma shares in Q1 2022, an estimated $20K.
Occidental Asset Management first reported a position in Matinas BioPharma in Q2 2021 and held it in 2 quarters.
Occidental Asset Management's Matinas BioPharma position peaked at $20K in Q4 2021.
56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Occidental Asset Management's 13F filing for Q1 2022, filed 4 May 2022.